Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Potent, orally bioavailable NK3 antagonist under study at Warner-Lambert

April 19, 1999

Preparation, compositions and administration of new carrier compounds reported by Emisphere

April 15, 1999

SBIR grant to Genetronics for gene therapy delivery research

April 15, 1999

Epicyte awarded SBIR and DARPA grants

April 14, 1999

Isis and Elan sign antisense agreement

April 14, 1999

Delsys and R.W. Johnson to collaborate on solid oral drug delivery technology

April 12, 1999

Metabolic Modulators and Chugai sign drug discovery agreement

April 9, 1999

CyDex and Allergan sign Captisol licensing agreement

April 9, 1999

Alkermes discontinues RMP-7/carboplatin brain tumor trial

April 8, 1999

Sibia Neurosciences licenses TBA technology to Bristol-Myers Squibb

April 8, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...